Investor Overview

Investor Overview

Webcast ImageWebcast
Reata Update on Kidney Function Data the LARIAT Study (Replay)
02/13/18 at 8:30 a.m. ET
Reata Update on Kidney Function Data the LARIAT Study
Tuesday, February 13, 2018 8:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (bardoxolone methyl and omaveloxolone) target the important transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
Read More >>
RETA (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$26.73
Change (%)0.00 (0.00%)
Volume0
Data as of 02/16/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock chart for: RETA.O.  Currently trading at $26.73 with a 52 week high of $40.88 and a 52 week low of $19.48.
Data provided by Nasdaq. Minimum 15 minutes delayed.

Investor Contact
Vineet Jindal
Vice President, Strategy
(855) 55-REATA
ir@reatapharma.com